期刊文献+

培养瓶制备腺病毒的收率研究 被引量:2

Improvement of the process for adenovirus production
下载PDF
导出
摘要 在293细胞培养体系中感染腺病毒后,分别培养48、72或96 h时收获病毒,比较产量和活性,结果表明培养72 h是高产的最佳收获时机;并讨论了毒种制备的规模、后续使用特点对制备方法的限制。 After infection with adenovirus in 293 cell culture system, adenovirus was harvested from 48 h, 72 h and 96 h culture, respectively. The yield and activity of the adenovirus were compared, and the optimum harvest time for high yield adenovirus was judged to be 72 h. The limitations of the scale of adenovirus preparation and the characteristics of subsequent use on the preparation were discussed.
作者 王爱霞 薛亮 胡国栋 WANG Aixia;XUE Liang;HU Guodong(Shanghai Sunway Biotech Co.,Ltd.,Shanghai 201206,China)
出处 《上海医药》 CAS 2020年第15期83-85,105,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 293细胞 腺病毒 毒种制备 病毒收获 非完全释放 完全释放 293 cell adenovirus virus preparation virus harvest incomplete release complete release
  • 相关文献

参考文献10

二级参考文献63

  • 1祁丽,顾铭,丛威.重组腺病毒生产技术研究进展[J].过程工程学报,2004,4(5):475-480. 被引量:1
  • 2薛惠斌,施军霞,朱文川,陈敏,钱其军.腺病毒CNHK200-hEndostatin质量控制方法的研究[J].第二军医大学学报,2007,28(9):1011-1014. 被引量:3
  • 3Peng Z.Current status of gendicine in China:recombinant human Ad-p53 agent for treatment of cancers[J].Hum Gene Ther,2005,16:1016-1027.
  • 4人基因治疗研究和制剂质量控制技术指导原则[EB/OL].国家食品药品监督管理局.http://www.sfda.gov.cn/cm sweb/webportal/w4278/A25922665.html[2005-05-30].
  • 5Lehmberg E,Traina J A,Chakel J A,et al.Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome[J].J Chromatogr B,1999,732:411-423.
  • 6Roitsch C,Achstetter T,Benchaibi M,et al.Characterization and quality control of recombinant adenovirus vectors for gene therapy[J].J Chromatogr B,2001,752:263-280.
  • 7Klyushnichenko V,Bernier A,Kamen A,et al.Improved high-performance liquid chromatographic method in the analysis of adenovirus particles[J].J Chromatogr B,2001,755:27-36.
  • 8Zhang W W,Koch P E,Roth J A.Detection of wild-type contamination in a recombinant adenoviral preparation by PCR[J].Biotechniques,1995,18:444-447.
  • 9Working P K,Lin A,Borellini F.Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses[J].Oncogene,2005,24:7792-7801.
  • 10Lusky M.Good manufacturing practice production of adenoviral vectors for clinical trials[J].Hum Gene Ther,2005,16:281-291.

共引文献47

同被引文献5

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部